Search

Your search keyword '"Girszyn, N"' showing total 242 results
Start Over Author "Girszyn, N"
242 results on '"Girszyn, N"'

1. POS1116 DEVELOPMENT AND VALIDATION OF A PATIENT-CENTERED AUTOEVALUATION QUESTIONNAIRE IN SYSTEMIC LUPUS ERYTHEMATOSUS: LUPIN

Author

Scherlinger, M., primary, Kleinmann, J. F., additional, Folliasson, A., additional, Riviere, M., additional, Rybak, R., additional, Malivoir, S., additional, Viallard, J. F., additional, Renou, F., additional, Lazaro, E., additional, Richez, C., additional, Roblot, P., additional, Puyade, M., additional, Baverez, C., additional, Hot, A., additional, Deligny, C., additional, Baillet, N., additional, Wendling, D., additional, Campagne, J., additional, Agard, C., additional, Jaussaud, R., additional, Moulinet, T., additional, Wahl, D., additional, Blaison, G., additional, Diot, E., additional, Ferreira-Maldent, N., additional, Marie, I., additional, Girszyn, N., additional, Perard, L., additional, André, M., additional, Orquevaux, P., additional, Servettaz, A., additional, Chasset, F., additional, Hervier, B., additional, Martin, T., additional, Fermont, C., additional, David, E., additional, Raffray, L., additional, Trefond, L., additional, Smets, P., additional, Lescanff, J., additional, Gottenberg, J. E., additional, Mariette, X., additional, Amoura, Z., additional, and Sibilia, J., additional

Published
2024
Full Text
View/download PDF

2. Approches thérapeutiques dans l’atteinte oculaire sévère de la maladie de Behçet : étude rétrospective multicentrique

Author

Hermant, A., primary, Nguyen, Y., additional, Cohen-Aubart, F., additional, Baudet, A., additional, Deroux, A., additional, Poindron, V., additional, Durel, C.A., additional, Girszyn, N., additional, Le Gouellec, N., additional, Rouviere, B., additional, Gil, H., additional, Maurier, F., additional, Noel, N., additional, Raffray, L., additional, De Boysson, H., additional, Faucher, B., additional, Godeau, B., additional, Lozac’h, P., additional, Bachmeyer, C., additional, Berezne, A., additional, Blaison, G., additional, Castel, B., additional, Gondran, G., additional, Groh, M., additional, Guffroy, A., additional, Keraen, J., additional, Magnant, J., additional, Monnier, S., additional, Blanche, P., additional, Monnet, D., additional, Brézin, A., additional, and Terrier, B., additional

Published
2023
Full Text
View/download PDF

4. Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study

Author

Canzian A, Venhoff N, Urban ML, Sartorelli S, Ruppert AM, Groh M, Girszyn N, Taillé C, Maurier F, Cottin V, de Moreuil C, Germain V, Samson M, Jachiet M, Denis L, Rieu V, Smets P, Pugnet G, Deroux A, Durel CA, Aouba A, Cathébras P, Deligny C, Faguer S, Gil H, Godeau B, Lifermann F, Phin-Huynh S, Ruivard M, Bonniaud P, Puéchal X, Kahn JE, Thiel J, Dagna L, Guillevin L, Vaglio A, Emmi G, Terrier B, French Vasculitis Study Group (FVSG), the European EGPA Study Group., Canzian, A, Venhoff, N, Urban, Ml, Sartorelli, S, Ruppert, Am, Groh, M, Girszyn, N, Taillé, C, Maurier, F, Cottin, V, de Moreuil, C, Germain, V, Samson, M, Jachiet, M, Denis, L, Rieu, V, Smets, P, Pugnet, G, Deroux, A, Durel, Ca, Aouba, A, Cathébras, P, Deligny, C, Faguer, S, Gil, H, Godeau, B, Lifermann, F, Phin-Huynh, S, Ruivard, M, Bonniaud, P, Puéchal, X, Kahn, Je, Thiel, J, Dagna, L, Guillevin, L, Vaglio, A, Emmi, G, Terrier, B, and French Vasculitis Study Group (FVSG), the European EGPA Study Group.

Subjects
Adult, Male, medicine.medical_specialty, Immunology, Birmingham Vasculitis Activity Score, Omalizumab, Churg-Strauss Syndrome, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Interquartile range, Recurrence, Internal medicine, medicine, Immunology and Allergy, Humans, Immunologic Factors, 030212 general & internal medicine, Treatment Failure, Adverse effect, Glucocorticoids, Aged, Retrospective Studies, 030203 arthritis & rheumatology, Biological Products, business.industry, Middle Aged, medicine.disease, Asthma, Treatment Outcome, Rituximab, Female, Vasculitis, business, Granulomatosis with polyangiitis, Mepolizumab, medicine.drug
Abstract

OBJECTIVE To describe the efficacy and safety of biologics for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA). METHODS A retrospective European collaborative study was conducted in patients with EGPA who received treatment with biologics for refractory and/or relapsing disease. RESULTS Among the 147 patients with EGPA included in the study, 63 received rituximab (RTX), 51 received mepolizumab (MEPO), and 33 received omalizumab (OMA). At the time of inclusion, the median Birmingham Vasculitis Activity Score (BVAS) was 8.5 (interquartile range [IQR] 5-13) in the RTX group, while the median BVAS in the OMA group was 2 (IQR 1-4.5) and the median BVAS in the MEPO group was 2 (IQR 1-5). In patients receiving RTX, the median BVAS declined both at 6 months (median 1, IQR 0-4.5) and at 12 months (median 0, IQR 0-2), and the frequency of remission, partial response, treatment failure, and stopping treatment due to adverse events was 49%, 24%, 24%, and 3%, respectively. For the treatment of glucocorticoid (GC)-dependent asthma, patients who received MEPO had a much better GC-sparing effect and overall response than did patients who received OMA. The frequency of remission, partial response, treatment failure, and stopping treatment due to adverse events was 15%, 33%, 48%, and 4%, respectively, in the OMA group and 78%, 10%, 8%, and 4%, respectively, in the MEPO group. Remission rates at 12 months were 76% and 82% among patients receiving MEPO at a doses of 100 mg and 300 mg, respectively. CONCLUSION These results suggest that RTX could be effective in treating relapses of EGPA vasculitis. MEPO is highly effective with a good safety profile in patients with GC-dependent asthma. Our data suggest that 100 mg MEPO monthly could be an acceptable dosage for first-line therapy in selected instances of EGPA, recognizing, however, that this has not been compared to the validated dosage of 300 mg monthly.

Published
2020

5. Essai randomisé, multicentrique évaluant l’efficacité et la tolérance de l’adalimumab, de l’anakinra et du tocilizumab dans les uvéites réfractaires non infectieuses (RUBI)

Author

Saadoun, D., Ghembaza, A., Sarah, T., Girszyn, N., Philip, B., S. P., Grégory, P., Marc, A., Mathilde, L., Thomas, R., Emmanuel, R., Hie, M., Gaëlle, C.R., Abad, S., Stanescu, D., Toutée, A., Gueudry, J., Bron, A., Kodjikian, L., Vincent, S., Fréderic, C., Titah, C., Emmanuel, H., Asma, M., Trad, S., Terrada, C., Nathalie, M., Domont, F., Anne-Claire, D., Maalouf, G., Vautier, M., Cacoub, P., Kristelle, D., Biard, L., and Bodaghi, B.

Published
2023
Full Text
View/download PDF

6. Efficacité des anti-TNF alpha dans la prise en charge de l’œdème maculaire cystoïde et des vascularites rétiniennes au cours des uvéites non-infectieuses : étude multicentrique BIOVAS

Author

Maalouf, G., primary, Leclercq, M., additional, Sève, P., additional, Bielefeld, P., additional, Rouviere, B., additional, Girszyn, N., additional, Moulinet, T., additional, Gueudry, J., additional, Sené, T., additional, Sene, D., additional, Cacoub, P., additional, Domont, F., additional, Desbois, A.C., additional, Sarah, T., additional, Bodaghi, B., additional, Biard, L., additional, and Saadoun, D., additional

Published
2020
Full Text
View/download PDF

7. Identification de variants du gène EPX au cours de la granulomatose éosinophilique avec polyangéite (Churg-Strauss)

Author

David, C., primary, Hamel, Y., additional, Smahi, A., additional, Diot, E., additional, Benhamou, Y., additional, Girszyn, N., additional, Le Gallou, T., additional, Lifermann, F., additional, Godmer, P., additional, Maurier, F., additional, Cottin, V., additional, Grados, A., additional, Aumaître, O., additional, Néel, A., additional, Pugnet, G., additional, Puéchal, X., additional, Mouthon, L., additional, Guillevin, L., additional, Bienvenu, T., additional, and Terrier, B., additional

Published
2020
Full Text
View/download PDF

8. Efficacité des biothérapies dans la prise en charge de l’œdème maculaire cystoïde au cours des uvéites non-infectieuses : étude multicentrique BIOVAS

Author

Leclercq, M., primary, Maalouf, G., additional, Sève, P., additional, Bielefeld, P., additional, Rouviere, B., additional, Girszyn, N., additional, Moulinet, T., additional, Gueudry, J., additional, Sené, T., additional, Sene, D., additional, Cacoub, P., additional, Domont, F., additional, Desbois, A.C., additional, Sarah, T., additional, Bodaghi, B., additional, Biard, L., additional, and Saadoun, D., additional

Published
2020
Full Text
View/download PDF

9. Efficacité du tocilizumab dans la prise en charge de l’œdème maculaire cystoïde et des vascularites rétiniennes au cours des uvéites non-infectieuses : étude multicentrique BIOVAS

Author

Leclercq, M., primary, Maalouf, G., additional, Sève, P., additional, Bielefeld, P., additional, Rouviere, B., additional, Girszyn, N., additional, Moulinet, T., additional, Gueudry, J., additional, Sené, T., additional, Sene, D., additional, Cacoub, P., additional, Domont, F., additional, Desbois, A.C., additional, Sarah, T., additional, Bodaghi, B., additional, Biard, L., additional, and Saadoun, D., additional

Published
2020
Full Text
View/download PDF

10. Efficacité des biothérapies dans la prise en charge des vascularites rétiniennes au cours des uvéites non-infectieuses: étude multicentrique BIOVAS

Author

Maalouf, G., primary, Leclercq, M., additional, Sève, P., additional, Bielefeld, P., additional, Rouviere, B., additional, Sené, T., additional, Girszyn, N., additional, Sene, D., additional, Moulinet, T., additional, Gueudry, J., additional, Cacoub, P., additional, Domont, F., additional, Desbois, A.C., additional, Sarah, T., additional, Bodaghi, B., additional, Biard, L., additional, and Saadoun, D., additional

Published
2020
Full Text
View/download PDF

44. Granulomatosis with polyangiitis and pregnancy: A case report and review of the literature.

Author

Daher, A, Sauvetre, G, Girszyn, N, Verspyck, E, Levesque, H, and Le Besnerais, M

Subjects
THERAPEUTIC use of immunoglobulins, GRANULOMATOSIS with polyangiitis diagnosis, ADRENOCORTICAL hormones, GESTATIONAL age, EVALUATION of medical care, VASCULITIS, DECISION making in clinical medicine, GRANULOMATOSIS with polyangiitis, DISEASE remission, PREGNANCY
Abstract

The association of granulomatosis with polyangiitis and pregnancy is rare and therapeutic options are limited by the risk of teratogenicity and fetotoxicity. There is a paucity of published literature to guide clinical decision-making in these cases. We report the case of a 26-year-old woman with no medical history who presented at 21 weeks of gestation with a bilateral sudden loss of hearing and erosive rhinitis. The diagnosis of granulomatosis with polyangiitis was confirmed radiologically and biologically. Corticosteroids were not enough to stabilize the disease and she received intravenous immunoglobulins with remission. A successful delivery of a healthy male newborn was done at 36 weeks. A review of all published literature on granulomatosis with polyangiitis in pregnancy between 1970 and 2017 is presented. Trial registration : Not applicable. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

45. Caractéristiques, devenir et réponse aux traitements chez les patients ayant une sarcoïdose réfractaire aux anti-TNF : analyse des données du registre STAT

Author

Thery-Casari, C., primary, Jamilloux, Y., additional, Bouvry, D., additional, Chapelon, A.C., additional, Marquet, A., additional, Bielefeld, P., additional, Schleinitz, N., additional, Girszyn, N., additional, Fain, O., additional, Bonnet, F., additional, Valeyre, D., additional, and Sève, P., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results